GLP-1 receptor agonists, medications like semaglutide and tirzepatide, may help some women with PMOS (polyendocrine metabolic ovarian syndrome, formerly called PCOS) by improving insulin resistance, reducing weight, and lowering androgen levels. However, these drugs are not a replacement for a full treatment approach that includes nutrition, exercise, sleep, and metabolic monitoring.

What Is PMOS and Why Does Insulin Resistance Matter?

In May 2026, the condition previously known as polycystic ovary syndrome (PCOS) was officially renamed polyendocrine metabolic ovarian syndrome (PMOS). The name change reflects a crucial shift in how doctors understand the condition: it is not simply an ovary problem, but a whole-body endocrine and metabolic disorder.

This distinction matters because PMOS affects far more than menstrual cycles and fertility. The condition can involve insulin resistance, elevated androgen levels, acne, facial hair growth, irregular ovulation, weight gain, inflammation, cholesterol changes, blood sugar problems, fatty liver risk, and increased cardiovascular risk.

Insulin resistance is particularly important. When insulin levels remain high, the ovaries can produce more androgens, the hormones responsible for acne, unwanted facial hair, scalp hair thinning, and ovulation problems. This is why simple advice to "eat less and move more" often fails for women with PMOS; the underlying metabolic dysfunction makes weight loss significantly harder.

How Do GLP-1 Medications Work for PMOS?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It signals fullness, supports insulin release, slows stomach emptying, and helps regulate blood sugar. GLP-1 receptor agonists mimic this hormone and are sold under brand names including Ozempic, Wegovy, Saxenda, and Victoza. Tirzepatide, sold as Mounjaro and Zepbound, works on both GLP-1 and GIP receptors but is often included in the broader GLP-1 conversation.

These medications may help women with PMOS by improving insulin sensitivity, lowering appetite, supporting weight loss, improving blood sugar control, and reducing some cardiometabolic risk markers.

What Does the Research Show?

The evidence for GLP-1 medications in PMOS is promising but not a miracle cure. A 2025 meta-analysis published in Scientific Reports found that GLP-1 receptor agonists reduced body weight, BMI, and insulin resistance in women with PCOS, although nausea, vomiting, and dizziness were more common side effects.

A 2024 meta-analysis found GLP-1 receptor agonists helped lower BMI, waist circumference, triglycerides, and total testosterone in women with PCOS living with obesity. Lower testosterone is significant because androgen excess is one of the primary reasons women struggle with acne, facial hair growth, and scalp hair thinning.

A 2026 systematic review in the European Journal of Endocrinology found GLP-1 receptor agonists were associated with modest short-term weight loss in women with PCOS and overweight or obesity. However, the authors emphasized that evidence for metabolic, reproductive, and psychological outcomes remains uncertain because available studies are limited.

Some studies suggest menstrual regularity and ovulation may improve, especially when weight loss and insulin sensitivity improve. That may be good news for women trying to restore ovulation, but it also means pregnancy can happen unexpectedly, so contraception and timing matter.

When Might GLP-1 Medications Be Right for You?

GLP-1 medications are not approved specifically for PMOS. Some are approved for type 2 diabetes or chronic weight management. In PMOS, they may be used when the clinical picture fits, especially when higher weight or metabolic risk is present.

According to the 2023 International Evidence-Based Guideline for PCOS, anti-obesity medications, including GLP-1 receptor agonists such as liraglutide and semaglutide, could be considered in addition to lifestyle intervention for adults with PCOS and higher weight.

Steps to Determine If GLP-1 Treatment Might Help

• Insulin and Blood Sugar Status: GLP-1 medications may be worth discussing with your provider if you have insulin resistance, prediabetes, type 2 diabetes, or elevated fasting insulin levels.
• Weight and Metabolic Health: You are overweight or obese, especially if weight gain is worsening blood sugar, cholesterol, blood pressure, fatty liver risk, inflammation, or joint pain.
• Appetite Dysregulation: You experience strong food noise, cravings, or appetite dysregulation that has not responded well to nutrition changes alone.
• Androgen-Related Symptoms: You have acne, facial hair growth, or scalp hair thinning, and insulin resistance appears to be part of the driver.
• Previous Treatment Attempts: You have tried nutrition changes, strength training, sleep support, stress management, or metformin, but your metabolic markers are still not improving.

Who Should Avoid GLP-1 Medications?

GLP-1 medications may not be a good fit if you are pregnant, trying to conceive right now, or not using reliable contraception when pregnancy is possible. Current PMOS guidance recommends effective contraception with GLP-1 receptor agonists because pregnancy safety data are lacking.

These medications also require caution in people with a personal or family history of medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2), history of pancreatitis, significant gallbladder disease, severe gastroparesis, or active eating disorder concerns.

Lean PMOS deserves special mention. Some women with PMOS are not overweight or obese, but they still have high androgens, irregular cycles, acne, or fertility issues. In those cases, weight loss may not be appropriate, and a GLP-1 may not be the best first move. If the main drivers are stress physiology, under-eating, gut inflammation, thyroid dysfunction, nutrient deficiencies, sleep disruption, or adrenal dysregulation, appetite suppression is not the best first move and may do harm.

Why GLP-1 Medications Are Not a Complete Solution

"GLP-1 medications may help some women with PMOS, especially when insulin resistance, higher weight, prediabetes, type 2 diabetes, or cardiometabolic risk are present. The best-supported benefits are weight reduction, BMI reduction, improved insulin resistance, and some improvements in androgen-related markers," explained Dr. Anna Garrett.

Dr. Anna Garrett, Functional Medicine Practitioner

However, Dr. Garrett emphasized that GLP-1s can be helpful but are not a substitute for a full PMOS plan. Even while taking these medications, women still need adequate protein, strength training, fiber, muscle protection, quality sleep, optimal gut health, and regular lab monitoring.

The approach should not be "take the shot and eat less." Instead, a comprehensive PMOS plan should address the full picture of what is happening with fasting insulin, A1C (a measure of average blood sugar over three months), glucose, lipids, liver enzymes, inflammatory markers, androgens, thyroid function, cortisol patterns, gut health, and nutrient status.

GLP-1 medications represent an important addition to the PMOS treatment toolkit, but they work best when combined with lifestyle changes, proper nutrition, exercise, and ongoing medical supervision. Women considering these medications should have a detailed conversation with their healthcare provider about whether they fit their specific situation and metabolic needs.